It's a wrap !
We are very proud to announce the end of the REPRINT consortium EUROSTARS project in which we have been involved for 3 years now.
This consortium was initially ranked 4 out of 644 projects reviewed, and the final results have not disappointed as the consortium has made it possible to reprogram tumor cells into antigen-presenting cells !
From reprogramming of human spheroids and 3D printed models to in vivo reprogramming of syngeneic and xenograft mouse models, this revolutionary therapy remodeled the tumor microenvironment, inducing T-cell expansion and remarkable tumor remissions. This in situ approach paves the way for the first human evaluation of this new cancer immunotherapy modality, that should start in 2027.
Concerning Antineo, thanks to the knowledge acquired during the REPRINT project, the bioprinted models obtained from tumor cells (CDX) are now robust and will make it possible to simulate tumor cells/immune cells/fibroblasts interactions in a 3D environment and to demonstrate the effects of innovative therapies in development.
We would like to thank all our partners Asgard Therapeutics, Lund University and InSphero for the quality of the scientific exchanges and their precious advices throughout the project.
